Denali Therapeutics Inc. (DNLI) PT Raised to $32 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $20.96 --0%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 2
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 2
Join SI Premium – FREE
Morgan Stanley analyst Sean Laaman raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $32.00 (from $30.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Denali Therapeutics Inc. (DNLI) PT Raised to $42 at Morgan Stanley
- Primoris Services Corporation (PRIM) PT Lowered to $110 at Needham
- Falabella SA (FALAB:CI) PT Raised to CLP7,700 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
